High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

Sylvain Manfredi, Olivier Bouche, Philippe Rougier, Laetitia Dahan, Marie Anne Loriot, Thomas Aparicio, Pierre Luc Etienne, Jean Pierre Lafargue, Cedric Lecaille, Jean Louis Legoux, Karine Le Malicot, Emilie Maillard, Thierry Lecomte, Faiza Khemissa, Gilles Breysacher, Pierre Michel, Emmanuel Mitry, and Laurent Bedenne

Abstract

High-dose FOLFIRI has an acceptable safety profile and promising efficacy. UDP-glucuronosyltransferase (UGT1A1) polymorphism may be predictive of toxicity and efficacy of irinotecan. This phase II study aimed to evaluate the combination of high-dose FOLFIRI plus bevacizumab in patients with previously untreated metastatic colorectal cancer (MCRC) based on their UGT1A1 genotype. Patients with the UGT1A1*1/1 (group 1) or *1/28 (group 2) genotype received bevacizumab plus high-dose FOLFIRI every 2 weeks. Using the Bryant and Day design with objective response rate and toxicity as the primary endpoints, 54 patients in each group were required with a planned interim analysis after inclusion of 17 patients per group. We planned to stop the trial at the interim analysis if ≤7 patients exhibited an objective response (OR) and/or ≥3 patients exhibited severe toxicity. At the interim analysis, ORs were higher than the number expected: 52.9% (group 1) and 58.8% (group 2). More than three toxic events occurred in both groups and, according to the interim analysis rule, the trial was closed due to unacceptable toxicity. Recruitment was stopped when 86 patients were included and an analysis on overall population was done for overall survival (OS) and progression-free survival (PFS). The median PFS was 10.7 months (group 1) and 10.4 months (group 2). The median OS was 25.5 months (group 1) and 23.9 months (group 2). This trial does not support the use of the intensive treatment with HD-FOLFIRI plus bevacizumab combination for MCRC in patients with the UGT1A1*1/1 or UGT1A1*1/28 genotype.

Introduction

Irinotecan is a camptothecin analogue with antitumor activity mediated through the inhibition of topoisomerase I. Irinotecan is metabolized by carboxylesterase to form active SN-38, which is further conjugated and detoxified by UDP-glucuronosyltransferase (UGT; ref. 1). Multiple factors determine SN-38 levels, among them UGT ability to inactivate SN-38 by glucuronidation seems to be of importance. Several polymorphisms in UGT, especially the UGT1A1 isoform, have been shown to influence the glucuronidation capacity and, consequently, the pharmacokinetics and toxicity of irinotecan. Different UGT1A1 genotypes have been described. Some of these genotypes are associated with the decreased activity of the corresponding enzyme isoform, leading to constitutional unconjugated jaundice, Crigler-Najjar or Gilbert's syndrome (2), or decreased SN-38 glucuronidation activity (3, 4). Accumulation of the active metabolite SN-38 would increase toxicity of irinotecan.

The most common (wild-type) UGT1A1 allele is believed to be UGT1A1*1. The UGT1A1*28 allele is associated with a 2-base pair (bp) insertion (TA) in the TATA box in the promoter, resulting in the sequence (TA)_2(TAA) (the most common sequence is (TA)_2(TAA)). This nucleotide change in the promoter region is associated with the reduced expression of the protein and, therefore, with the decreased activity of SN-38 glucuronidation (a 50% decrease in UGT1A1*28/UGT1A1*28 patients and a 25% decrease...
in UGT1A1/CUGT1A1*28 patients compared with UGT1A1/CUGT1A1*1 patients (4).

Taking into account both toxicity and compliance, a clinical trial established the recommended dose of irinotecan combined with the biweekly LV5FU2 regimen to be 180 mg/m² every 2 weeks, although MTD criteria were not met at doses up to 260 mg/m² (5).

Results from a genotype-driven phase I study suggested, however, that this recommended dose is considerably lower than the dose that can be tolerated by patients with normal SN-38 glucuronidation (6). Therefore, because there is a dose linearity of irinotecan pharmacokinetics with proportional increases in the AUC of both irinotecan and SN-38 with higher doses of irinotecan (7), dose intensification may be a way to optimize the efficacy of treatments in selected patients (6). The combination of high-dose irinotecan (260 mg/m²) with the simplified LV5FU2 regimen (HD-FOLFIRI regimen) was shown to be feasible with an acceptable safety profile and promising efficacy data (8).

The combination of 5-fluorouracil, irinotecan, and bevacizumab is a standard treatment for metastatic colorectal cancer (MCRC; ref. 9). Adding bevacizumab to this optimized chemotherapy regimen may be of interest.

The aim of this phase II study was to evaluate the tolerance and efficacy of the HD-FOLFIRI regimen in combination with bevacizumab (B) in patients with the UGT1A1/CUGT1A1*1 and CUGT1A1*28 genotypes.

### Patients and Methods

#### Participants

This study was an open-label, nonrandomized, phase II trial. Patients 18 to 74 years old with a World Health Organization (WHO) performance status (PS) of less than 2 and nonresectable MCRC who had not previously been treated were eligible for inclusion if they exhibited the UGT1A1/CUGT1A1*1 or UGT1A1/CUGT1A1*28 genotype. We excluded patients with UGT1A1/CUGT1A1*28/28 genotypes because this genotype is present in only 9.8% to 11% of the population (10) and would increase dramatically the number of patients to screen and to include and the time length of the study. Previous adjuvant chemotherapy without irinotecan was allowed if the last administration was performed at least 6 months before inclusion in the study. At least one lesion had to be measurable according to RECIST criteria. Patients had to have adequate bone marrow and liver and renal function (i.e., hemoglobin concentration ≥9 g/dL, neutrophil cell count ≥1.5 × 10⁹ cells/L, platelet count ≥100 × 10⁹/L, serum bilirubin concentration ≤1.5 times the upper limit of normal, and alkaline phosphatase concentration ≤2.5 times the upper limit of normal; ≤3 times the upper limit of normal in cases of liver metastases). Patients were not eligible if they exhibited brain metastases or a serious concomitant medical disorder that would prevent the safe administration of chemotherapy or would be likely to interfere with study assessments. Written informed consent was obtained from all patients before study entry. The study was approved by the Boulogne-Billancourt Hospital (France) ethics committee and was registered at ClinicalTrials.gov, number NCT00628810.

#### Genotyping

UGT1A1 genotyping was performed on blood samples (10-mL EDTA tubes) after obtaining written consent from the patient. DNA was extracted using the QiAmP blood DNA extraction kit (Qiagen) in the Laboratory of Biochemistry at the “Hospital Européen Georges Pompidou” in Paris. After quantification, DNA was stored at −20°C until genotyping was performed. The UGT1A1/CUGT1A1*28 allele of the gene was detected by fragment analysis. All alleles were characterized after the amplification of the DNA fragment using PCR by capillary electrophoresis for polymorphisms (9700 sequencing, Applied Biosystems). Genotyping results were sent within 10 days to the investigator.

#### Statistical considerations and trial design

The goal of adding targeted therapy to chemotherapy is generally to increase efficacy without increasing unacceptable toxicity. We have considered, after literature analysis, that a reasonable expected objective response rate (ORR) rate must be at least 60% (ORR for FOLFIRI Bevacizumab combination is around 58% (11), 49% for FOLFIRI (12), 54% for HD FOLFIRI (8), and the unacceptable level of severe toxicity must be under 20%.

Two groups of patients were considered according to their UGT1A1 genotype (Group 1: UGT1A1/CUGT1A1*1; Group 2: UGT1A1/CUGT1A1*28). The frequency of UGT1A1/CUGT1A1*28 alleles is reported to be about 32% in the Caucasian population (10). A Bryant and Day design was used with the ORR at 6 months and toxicity as the primary endpoints [independent review, H0: insufficient efficacy, ORR ≤40%; H1: expected efficacy ORR ≥60%, grade 4 or febrile neutropenia or grade 3–4 diarrhea (NCI CTC Version 2.0); H0: unacceptable toxicity, grade 3–4 toxicity ≥20%; H1: acceptable toxicity, grade 3–4 toxicity ≤5%]. An interim analysis was planned after the inclusion of 17 patients per group after 6 months of follow-up; if 7 patients or less had no objective response or/and 3 or more patients had unacceptable toxicity, the study would be stopped for futility, if 8 or more patients had an objective response or/and 2 or less patients had unacceptable grade 3–4 toxicity, 37 more patients per group were required for a total of 108 patients, 54 in each group, (α 5% and power 80%).

The secondary endpoints included progression-free survival (PFS) and overall survival (OS). PFS was calculated as the interval from the date of inclusion in the study to the first report of disease progression or death from any cause or cutoff date. OS was calculated as the interval from the date of inclusion until death from any cause or until the date of the last follow-up or cutoff date. The Kaplan–Meier method was used to estimate the OS and PFS curves. The cutoff date for the final analysis was January 01, 2011. All analyses were based on the intent to treat principle. All tests were two sided, and P values less than 0.05 were regarded as significant. Data were analyzed using the STATA statistical software (version 10.0). In the absence of very serious adverse events, the study was planned not to stop enrollment during the interim analysis and finally 86 patients were included, we present here the results of the interim analysis and in parallel of the overall population included.

#### Treatment

Patients were treated with bevacizumab 5 mg/kg D1, irinotecan 260 mg/m² D1, 46-hour infusion D1-2, 5FU 400 mg/m² D1, 5FU 400 mg/m² IV bolus D1, and 5FU 2,400 mg/m² 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.

Prophylactic G-CSF administration was not allowed as a primary prevention. G-CSF use was recommended in the case of grade 4 neutropenia for more than 7 days, febrile neutropenia, infection with concomitant grade 3–4 neutropenia, or nonrecovery of neutrophil cell counts ≥1,500/mm³ after 1 week.
Drug dose reductions and delays in the case of hematologic or nonhematologic toxicities were detailed in the protocol. The treatment was stopped in the event of patient withdrawal, disease progression, or unacceptable toxic effects (nonhematologic grade 4 toxicity, nonrecovery from grade 3 toxicity after two dose adjustments, or nonrecovery after a 2-week treatment delay). Any dose reduction was permanent.

The tumor response was assessed every four cycles with CT or MRI according to the RECIST criteria. An objective response had to be confirmed by CT or MRI after 4 weeks. An external radiologic review was performed. Toxic effects were graded according to the National Cancer Institute Common Toxicity Criteria (version 2.0) until 4 weeks after the end of study treatments. At every visit, patients underwent history taking, physical examination, hematologic tests, and biochemical tests. An independent data monitoring committee reviewed the safety data on a regular basis.

Results

Patients were recruited between January 29, 2007, and January 30, 2008, for the first 34 patients analyzed in the interim analysis, December 11, 2008, for the final 86 included patients, at 20 centers in France. Thirty-four patients were analyzed in the interim analysis (17 in each group). As study inclusion was not stopped before the availability of the IA results, a total of 86 patients were included (40 patients in group 1 and 46 patients in group 2). One patient in group 2 was never treated because brain metastases were discovered after the patient’s inclusion in the study. The flow chart of the study is presented in Fig. 1.

Patient characteristics

Interim analysis. The baseline characteristics of the patients analyzed in the interim analysis are presented in Table 1. The median patient age was 59 years (range: 52–75 years) in group 1 and 57 years (range: 44–72 years) in group 2. The WHO PS was 0–1 for 94.1% of the patients in both groups, but only 29.4% of the patients had a PS equal to 0 in group 1, compared with 52.9% in group 2. The primary tumor location was the colon and rectum in respectively, 58.8% and 41.2% of the patients in group 1 and 88.2% and 11.8% of the patients in group 2. Patients of group 2 had more frequently liver metastasis than patients of group 1, respectively, 88.2% and 52.9%, lung metastasis was more frequent in group 1 than in group 2: 58.8% and 11.8%.

Overall population. The median population age was 59 and 61 years for group 1 and group 2. The WHO PS was 0–1, respectively, for 92.5% and 91.3% of the patients. The primary tumor location was the colon for 70.0% in the group 1 and 73.9% in the group 2. Liver metastasis rates were, respectively, 72.5% and 84.8% for group 1 and 2, 35.0% and 26.1% for lung metastasis.

Treatment administration

Interim analysis. The median duration of treatment was 14 months (range: 1–28 months) in group 1 and 6.5 months (range: 0–25 months) in group 2 (Table 2). The median dose per cycle for cycles 1 to 4 was similar in both groups, but the patients in group 2 received a median of 12 treatment cycles (range: 0–30 cycles), compared with 22 cycles (range: 4–38 cycles) for the patients in group 1.

Overall population. The median duration of treatment was similar in the two groups: 7.0 months. The median dose per cycles 1 to 4 was similar in the both groups, and the patients received the same median number of cycles: 14.5 for group 1 and 13.5 for group 2.

Primary endpoint results

Interim analysis. In both groups, the confirmed ORR, as estimated by the independent central review, was higher than the number (>7) required by the stopping rule [9 (52.9%) and 10 (58.8%) objective responses in group 1 and group 2, respectively].
Three or more toxic events occurred in both groups (group 1: 7 events; group 2: 3 events), and the interim analysis stopping rules required less than 3 events to continue the trial (Table 3). The trial was therefore closed to inclusion after the results of the interim analysis.

**Overall population.** However, during the interim analysis and the availability of the results, recruitment was ongoing and finally a total of 86 patients were included (40 patients in group 1 and 46 patients in group 2). ORR was 45.0% in group 1 and 56.5% in group 2. ORR was equally frequent in the two groups.

Arterial hypertension rate was similar in the both groups 

**Tolerance**

**Interim analysis.** Toxicities by group are presented in Table 4. There was no death due to toxicity. All the patients experienced at least one adverse event, and 94.1% and 81.2% of the patients in group 1 and group 2, respectively, exhibited at least grade 3–4 toxicity.

Severe diarrhea occurred in 23.5% of the patients in group 1 and in 12.5% of the patients in group 2, whereas severe neutropenia was more frequent in group 2 (37.5% vs. 29.4%). Bevacizumab-related adverse events did not differ between the groups [except for grade 3–4 venous thromboembolic events (VTE), which occurred in 23.6% of patients in group 1 vs. 6.2% in group 2]. Arterial hypertension was observed in 23.5% of the patients in group 1 compared with 6.2% in group 2. Only one patient in each group exhibited grade 3 arterial hypertension. Approximately half of the patients exhibited epistaxis (mainly grade 1–2) in each group. Cerebral ischemia occurred in one patient in group 1.

**Overall population.** About 75.0% and 82.2% of patients of groups 1 and 2 exhibited at least one grade 3–4 toxicity. Severe diarrhea and VTE were more frequent in group 1 than in group 2, whereas severe neutropenia was more frequent in group 2 than in group 1. Arterial hypertension rate was similar in the both group. Epistaxis was equally frequent in the two groups.

**PFS and OS on the overall population (Table 5)**

The median PFS was 10.7 months (95% confidence intervals; CI, 8.5–13.1) in group 1 and 10.4 months (95% CI, 8.8–12.3) in group 2 (nonsignificant: NS). The median OS was 25.5 months.
(95% CI, 21.7–36.6) in group 1 and 23.9 months (95% CI, 18–37.1) in group 2 (NS).

Discussion

Optimization of medical treatment to improve efficacy with better tolerance is an important goal in the management of MCRC patients.

According to irinotecan metabolism, the standard dose of 180 mg/m² every 2 weeks may not be the optimal dose for patients with the UGT1A1*1/1 or *1/28 genotype (13). Previous studies demonstrated the feasibility and interest of higher doses of irinotecan in patients as monotherapy (7, 14) or in combination with 5FU: FOLFIRI regimen (8). The important interpatient variability for irinotecan pharmacokinetic can be, at least partly, explained by the UGT1A1*28 polymorphism (15).

The link between the UGT1A1*28 allele and the increase in SN-38 and the occurrence of diarrhea and leukopenia during irinotecan therapy suggested by retrospective studies (16–18) was prospectively reported by Innocenti and colleagues (19). In this study, the UGT1A1 genotype and haplotype were correlated with SN-38 pharmacology and the incidence of severe neutropenia. The rate of grade 4 neutropenia was 50% among *28/28 patients and 12.5% among *1/28 patients, and there was no grade 4 neutropenia among *1/1 patients. The prevalence of grade 3 diarrhea was 5% (1 *28/28 and 2 *1/28 patients, no grade 4 diarrhea). In the PETACC-3 trial, the risk of severe hematologic toxicity was increased among patients with homozygous UGT1A1*28 genotype (20). A recent meta-analysis reported that although the toxicity relationships were much stronger with the UGT1A1*28 homozygous variant, associations were also found with the UGT1A1*28 heterozygous variant (21). At least three prospective randomized phase III trials (22–24). However, did not confirm these initial results, suggesting that the influence of the UGT1A1*28 allele on the toxicity of irinotecan is modest and that its assessment should not be mandatory in routine clinical practice (23).

In a phase II study, 35 unselected patients were treated with the HD-FOLFIRI regimen as the first-line treatment of MCRC

### Table 3. Results of primary endpoint

<table>
<thead>
<tr>
<th></th>
<th>n = 34</th>
<th>Interim population</th>
<th>Overall population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 17</td>
<td>Group 1</td>
<td>n = 17</td>
</tr>
<tr>
<td></td>
<td>n = 17</td>
<td>Group 2</td>
<td>n = 17</td>
</tr>
<tr>
<td>Confirmed ORR n (%)</td>
<td>17 (100)</td>
<td>9 (52.9)</td>
<td>10 (58.8)</td>
</tr>
<tr>
<td>(interim analysis stopping rules required &gt;7 events)</td>
<td></td>
<td>10 (58.8)</td>
<td>11 (25.0)</td>
</tr>
<tr>
<td>Considered toxic events total number of patients (interim analysis stopping rules required &lt;3 events)</td>
<td>3 (17)</td>
<td>7 (11)</td>
<td>1 (11)</td>
</tr>
<tr>
<td>Grade 4 neutropenia</td>
<td></td>
<td>2a</td>
<td>3b</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Grade 3 diarrhea</td>
<td></td>
<td>4b</td>
<td>2b</td>
</tr>
<tr>
<td>Grade 4 diarrhea</td>
<td></td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

NOTE: Group 1: UGTA1*1/UGTA1*1; Group 2: UGTA1*1/UGTA1*28.

a1 patient in group 2 was never treated because brain metastases were discovered after the patient’s inclusion.

b1 patient with grade 4 neutropenia and grade 3 diarrhea.

c1 patient with grade 4 neutropenia and febrile neutropenia.

d1 patient with febrile neutropenia.

### Table 4. Adverse events (all cycles)

<table>
<thead>
<tr>
<th></th>
<th>n = 34</th>
<th>Interim population</th>
<th>Overall population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 17</td>
<td>Group 1</td>
<td>n = 17</td>
</tr>
<tr>
<td></td>
<td>n = 17</td>
<td>Group 2</td>
<td>n = 17</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>Grade 3–4</td>
<td>All</td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td></td>
<td>n (%)</td>
</tr>
<tr>
<td>Any</td>
<td>17 (100)</td>
<td>16 (94.1)</td>
<td>16 (100)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>All</td>
<td>17 (100)</td>
<td>16 (94.1)</td>
<td>16 (100)</td>
</tr>
<tr>
<td>Grade 3–4</td>
<td>13 (81.2)</td>
<td>11 (68.7)</td>
<td>12 (75.0)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>12 (70.6)</td>
<td>4 (23.5)</td>
<td>11 (68.7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>15 (76.5)</td>
<td>1 (5.9)</td>
<td>12 (75.0)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>10 (56.3)</td>
<td>0 (0.0)</td>
<td>10 (62.5)</td>
</tr>
<tr>
<td>Mucositis</td>
<td>9 (52.9)</td>
<td>1 (5.9)</td>
<td>7 (45.8)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>8 (47.1)</td>
<td>0 (0.0)</td>
<td>9 (56.3)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>6 (35.3)</td>
<td>0 (0.0)</td>
<td>6 (37.5)</td>
</tr>
<tr>
<td>VTE</td>
<td>7 (41.2)</td>
<td>2 (12.5)</td>
<td>4 (25.0)</td>
</tr>
<tr>
<td>ATE</td>
<td>1 (5.9)</td>
<td>0 (0.0)</td>
<td>2 (12.5)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>15 (76.5)</td>
<td>12 (75.0)</td>
<td>14 (87.5)</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>2 (11.8)</td>
<td>1 (5.9)</td>
<td>2 (12.5)</td>
</tr>
<tr>
<td>Anemia</td>
<td>16 (94.1)</td>
<td>1 (5.9)</td>
<td>11 (68.7)</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>6 (35.3)</td>
<td>0 (0.0)</td>
<td>6 (37.5)</td>
</tr>
</tbody>
</table>

NOTE: Group 1: UGTA1*1/UGTA1*1; Group 2: UGTA1*1/UGTA1*28.

Abbreviations: VTE, venous thromboembolic event; ATE, arterial thromboembolic event.

*1 patient in group 2 was never treated because brain metastases were discovered after the patient’s inclusion.
The addition of bevacizumab to the FOLFIRI HD regimen, compared with the trial by Ducruex and colleagues, in which a 54% ORR was reported, is also questionable (8).

In conclusion, this trial does not provide a convincing argument to support the adoption of the intensive treatment with HD-FOLIRI plus bevacizumab combination for MCRC in patients with the UGT1A1*1/*1 or UGT1A1*1/*28 genotype. The overall response rate reached in our study is not superior to standard treatments.

Disclosure of Potential Conflicts of Interest
O. Bouché has received speakers bureau honoraria from Lilly. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: O. Bouché, P. Rougier, J.L. Legoux, T. Lecomte, E. Mitry, L. Bedenne
Development of methodology: P. Rougier, M.A. Loriot, T. Lecomte, L. Bedenne
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): O. Bouché, P. Rougier, M.A. Loriot, T. Aparicio, J.P. Lafague, P.L. Etienne, C. Lécaille, J.L. Legoux, T. Lecomte, F. Khemissa, C. Brysacher, P. Michel, E. Mitry, L. Bedenne
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Manfredi, K. Le Malicot, E. Maillard, T. Lecomte, E. Mitry
Writing, review, and/or revision of the manuscript: S. Manfredi, O. Bouché, P. Rougier, L. Dahan, T. Aparicio, K. Le Malicot, E. Maillard, T. Lecomte, E. Mitry, L. Bedenne
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Manfredi, C. Lécaille, K. Le Malicot, L. Bedenne
Study supervision: E. Mitry

Acknowledgments
The authors thank Marie Moreau, Floline Ricard, and Franck Bonnetain.

Grant Support
All the authors received grants from La Ligue Nationale Contre le Cancer, Chugai, and Pfizer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 21, 2015; revised August 5, 2015; accepted August 21, 2015; published OnlineFirst October 22, 2015.


Table 5. PFS and OS (overall population)

<table>
<thead>
<tr>
<th></th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>40</td>
<td>46</td>
</tr>
<tr>
<td>Median PFS (mo)</td>
<td>10.7</td>
<td>10.4</td>
</tr>
<tr>
<td>IC (95%)</td>
<td>(8.5–13.1)</td>
<td>(8.8–12.3)</td>
</tr>
<tr>
<td>Median OS (mo)</td>
<td>25.5</td>
<td>23.9</td>
</tr>
<tr>
<td>IC (95%)</td>
<td>(21.7–36.6)</td>
<td>(18.0–37.1)</td>
</tr>
<tr>
<td>P</td>
<td>0.8</td>
<td>0.6</td>
</tr>
</tbody>
</table>

References


Molecular Cancer Therapeutics

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

Sylvain Manfredi, Olivier Bouché, Philippe Rougier, et al.


Updated version

Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-15-0293

Cited articles

This article cites 25 articles, 13 of which you can access for free at:
http://mct.aacrjournals.org/content/14/12/2782.full.html#ref-list-1

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.